Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center
Figure 1
Kaplan-Meier analysis of the neoadjuvant group and adjuvant group. OS (overall survival) and PFS (progression-free survival) between the two groups ((a), (b)); OS between the two groups without metastasis (c); OS between the two groups with metastasis (d); ((e), (f)) Kaplan-Meier analysis of the Ki-67 positive and negative patients in the neoadjuvant group. Ki-67 negative patients had greater OS benefits than Ki-67 positive patients in the neoadjuvant group (e). There was also a trend towards better PFS benefits in Ki-67 negative patients than positive patients, although the difference did not reach statistical significance (f).
